Analyzing Cue Biopharma (CUE) & Its Rivals

Cue Biopharma (NASDAQ:CUE) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Cue Biopharma to similar companies based on the strength of its risk, valuation, dividends, earnings, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares Cue Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-435.83%	-620.06%	-291.15%
Cue Biopharma Competitors	-12,323.33%	-195.38%	-30.39%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Cue Biopharma and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1	1	0	1	2.33
Cue Biopharma Competitors	9861	15274	45589	1597	2.54

Cue Biopharma currently has a consensus price target of $83.00, indicating a potential upside of 344.80%. As a group, “Biotechnology” companies have a potential upside of 120.20%. Given Cue Biopharma’s higher probable upside, analysts plainly believe Cue Biopharma is more favorable than its rivals.

Risk & Volatility

Cue Biopharma has a beta of 2.79, meaning that its stock price is 179% more volatile than the S&P 500. Comparatively, Cue Biopharma’s rivals have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.

Valuation & Earnings

This table compares Cue Biopharma and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cue Biopharma	$27.47 million	-$26.60 million	-0.69
Cue Biopharma Competitors	$732.70 million	$12.23 million	-18.09

Cue Biopharma’s rivals have higher revenue and earnings than Cue Biopharma. Cue Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cue Biopharma rivals beat Cue Biopharma on 7 of the 12 factors compared.

About Cue Biopharma

Cue Biopharma, Inc. is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is designed to selectively activate a patient’s own T cells against disease-associated antigens while minimizing broad immune-system activation. Cue Biopharma’s product candidates are based on its Immuno-STAT (Selective Targeting and Alteration of T cells) platform, which uses biologic molecules intended to engage specific T-cell receptors and deliver immune-modulating signals.